Investors
News & Events
Contact Us
Home
Who We Are
Company Overview
Management Team
Board of Directors
Partners
Pipeline
Pipeline
Clinical Trials
Investigator Sponsored Research
Expanded Access Policy
Proprietary Programs
IRAK1/4
RIPK1
COVID-19
Partnered Programs
BerGenBio
Daiichi-Sankyo
Forma
Grifols
Kissei
Lilly
Medison
Knight
Products
Join Our Team
Life at Rigel
Our Values
Benefits
Current Openings
Investors
News & Events
Contact Us
Press Releases
Investors
Investors
Overview
News & Events
Press Releases
Events & Presentations
Email Alerts
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
FAQ
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Analyst Coverage
Governance
Management Team
Board of Directors
Board Committees
Governance Documents
News & Events
Press Releases
Events & Presentations
Email Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Category
All Releases
Financial Releases
Search terms
Search News
Nov 24, 2014 7:30am EST
Rigel Announces Executive Management Changes
Nov 04, 2014 7:30am EST
Rigel Announces Third Quarter 2014 Financial Results
Aug 13, 2014 7:30am EDT
R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
Aug 05, 2014 7:30am EDT
Rigel Announces Second Quarter 2014 Financial Results
Jul 16, 2014 7:30am EDT
Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
May 29, 2014 7:30am EDT
Rigel to Present at Jefferies 2014 Global Healthcare Conference
May 07, 2014 7:30am EDT
Rigel Announces First Quarter 2014 Financial Results
Apr 30, 2014 7:30am EDT
Rigel Announces Webcast of Investor Day on May 6, 2014
Mar 06, 2014 7:30am EST
Rigel Announces Publication of R118 AMPK Activator Research
Mar 04, 2014 7:30am EST
Rigel Announces Fourth Quarter and Year End 2013 Financial Results
Previous
1…
17
18
19
20
21
22
23
24
25
26
…37
Next
Email Alerts
RSS News Feed
